Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 70

1.

Panitumumab in combination with modified docetaxel/cisplatin/5-fluorouracil as first-line treatment in gastric and gastroesophageal junction adenocarcinomas: a multicenter phase II study by the Hellenic Oncology Research Group.

Kentepozidis N, Economopoulou P, Liontos M, Kotsakis A, Boukovinas I, Vardakis N, Kontopodis E, Prinarakis E, Skaltsi T, Souglakos J, Georgoulias V.

Ann Gastroenterol. 2018 Nov-Dec;31(6):698-704. doi: 10.20524/aog.2018.0311. Epub 2018 Sep 14.

2.

Prognostic significance of CEACAM5mRNA-positive circulating tumor cells in patients with metastatic colorectal cancer.

Messaritakis I, Sfakianaki M, Papadaki C, Koulouridi A, Vardakis N, Koinis F, Hatzidaki D, Georgoulia N, Kladi A, Kotsakis A, Souglakos J, Georgoulias V.

Cancer Chemother Pharmacol. 2018 Nov;82(5):767-775. doi: 10.1007/s00280-018-3666-9. Epub 2018 Aug 9.

PMID:
30094617
3.

Nab-paclitaxel as second-line treatment in advanced gastric cancer: a multicenter phase II study of the Hellenic Oncology Research Group.

Katsaounis P, Kotsakis A, Kentepozidis N, Polyzos A, Bakogeorgos M, Koinis F, Vamvakas L, Vardakis N, Kalbakis K, Boukovinas I, Varthalitis II, Prinarakis E, Georgoulias V, Souglakos J.

Ann Gastroenterol. 2018 Jan-Feb;31(1):65-70. doi: 10.20524/aog.2017.0215. Epub 2017 Nov 27.

4.

Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG).

Kentepozidis N, Economopoulou P, Christofyllakis C, Chelis L, Polyzos A, Vardakis N, Koinis F, Vamvakas L, Katsaounis P, Kalbakis K, Nikolaou C, Georgoulias V, Kotsakis A.

Clin Transl Oncol. 2017 Mar;19(3):317-325. doi: 10.1007/s12094-016-1532-y. Epub 2016 Aug 4.

PMID:
27492015
5.

Docetaxel, gemcitabine and bevacizumab as salvage chemotherapy for HER-2-negative metastatic breast cancer.

Kontopodis E, Kentepozidis N, Christophyllakis Ch, Boukovinas I, Kalykaki A, Kalbakis K, Vamvakas L, Agelaki S, Kotsakis A, Vardakis N, Georgoulias V, Mavroudis D.

Cancer Chemother Pharmacol. 2015 Jan;75(1):153-60. doi: 10.1007/s00280-014-2628-0. Epub 2014 Nov 15.

PMID:
25398698
6.

A 52-year-old-male patient with metastatic non-small-cell lung cancer and recurrent venous thromboembolism in unusual sites despite anticoagulation.

Matikas A, Vardakis N, Souglakos J, Georgoulias V.

BMJ Case Rep. 2013 Sep 17;2013. pii: bcr2013200502. doi: 10.1136/bcr-2013-200502.

7.

A phase II study of metronomic oral vinorelbine administered in the second line and beyond in non-small cell lung cancer (NSCLC): a phase II study of the Hellenic Oncology Research Group.

Kontopodis E, Hatzidaki D, Varthalitis I, Kentepozidis N, Giassas S, Pantazopoulos N, Vardakis N, Rovithi M, Georgoulias V, Agelaki S.

J Chemother. 2013 Feb;25(1):49-55. doi: 10.1179/1973947812Y.0000000050.

PMID:
23433445
8.

Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumour cells in patients with early breast cancer.

Xenidis N, Perraki M, Apostolaki S, Agelaki S, Kalbakis K, Vardakis N, Kalykaki A, Xyrafas A, Kakolyris S, Mavroudis D, Georgoulias V.

Br J Cancer. 2013 Feb 19;108(3):549-56. doi: 10.1038/bjc.2012.597. Epub 2013 Jan 17.

9.

A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial.

Saridaki Z, Androulakis N, Vardakis N, Vamvakas L, Kabouraki E, Kalbakis K, Hatzidaki D, Voutsina A, Mavroudis D, Georgoulias V, Souglakos J.

Br J Cancer. 2012 Dec 4;107(12):1932-7. doi: 10.1038/bjc.2012.509. Epub 2012 Nov 20.

10.

Paclitaxel in combination with carboplatin as salvage treatment in patients with castration-resistant prostate cancer: a Hellenic oncology research group multicenter phase II study.

Kentepozidis N, Soultati A, Giassas S, Vardakis N, Kalykaki A, Kotsakis A, Papadimitraki E, Pantazopoulos N, Bozionellou V, Georgoulias V.

Cancer Chemother Pharmacol. 2012 Jul;70(1):161-8. doi: 10.1007/s00280-012-1896-9. Epub 2012 Jun 3.

PMID:
22660737
11.

Paclitaxel plus bevacizumab in patients with chemoresistant relapsed small cell lung cancer as salvage treatment: a phase II multicenter study of the Hellenic Oncology Research Group.

Mountzios G, Emmanouilidis C, Vardakis N, Kontopodis E, Hatzidaki D, Popis E, Karachaliou N, Kotsakis A, Agelidou M, Georgoulias V.

Lung Cancer. 2012 Jul;77(1):146-50. doi: 10.1016/j.lungcan.2012.02.002. Epub 2012 Mar 13.

PMID:
22418242
12.

A multicenter phase II trial of docetaxel plus gemcitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer.

Karachaliou N, Kouroussis Ch, Papakotoulas P, Kalbakis K, Tryfonidis K, Vardakis N, Poppis E, Georgoulias V, Mavroudis D.

Cancer Chemother Pharmacol. 2012 May;69(5):1345-52. doi: 10.1007/s00280-012-1824-z. Epub 2012 Feb 17.

PMID:
22349809
13.

A phase II trial of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer.

Pallis AG, Voutsina A, Kentepozidis N, Giassas S, Papakotoulas P, Agelaki S, Tryfonidis K, Kotsakis A, Vamvakas L, Vardakis N, Georgoulias V.

Clin Lung Cancer. 2012 Mar;13(2):129-35. doi: 10.1016/j.cllc.2011.08.004. Epub 2011 Oct 14.

PMID:
22000696
14.

Clinical outcome of patients with various advanced cancer types vaccinated with an optimized cryptic human telomerase reverse transcriptase (TERT) peptide: results of an expanded phase II study.

Kotsakis A, Vetsika EK, Christou S, Hatzidaki D, Vardakis N, Aggouraki D, Konsolakis G, Georgoulias V, Christophyllakis Ch, Cordopatis P, Kosmatopoulos K, Mavroudis D.

Ann Oncol. 2012 Feb;23(2):442-9. doi: 10.1093/annonc/mdr396. Epub 2011 Aug 25.

PMID:
21873272
15.

Metronomic vinorelbine plus bevacizumab as salvage therapy for patients with metastatic breast cancer.

Saloustros E, Kalbakis K, Vardakis N, Kalykaki A, Milaki G, Rovithi M, Agelaki S, Saridaki Z, Georgoulias V, Mavroudis D.

J BUON. 2011 Apr-Jun;16(2):215-8.

PMID:
21766488
16.

Chemotherapy with gemcitabine, cisplatin, and docetaxel in the treatment for patients with muscle-invasive bladder cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).

Boukovinas I, Androulakis N, Kentepozidis N, Polyzos A, Papakotoulas P, Ziras N, Kotsakis A, Vardakis N, Karampeazis A, Markos V, Kostakopoulos A, Constantinides CA, Samonis G, Mavroudis D, Georgoulias V.

Cancer Chemother Pharmacol. 2012 Feb;69(2):351-6. doi: 10.1007/s00280-011-1694-9. Epub 2011 Jul 12.

PMID:
21748359
17.

Docetaxel vs. vinorelbine in elderly patients with advanced non--small-cell lung cancer: a hellenic oncology research group randomized phase III study.

Karampeazis A, Vamvakas L, Agelidou A, Kentepozidis N, Chainis K, Chandrinos V, Vardakis N, Pallis AG, Christophyllakis C, Georgoulias V.

Clin Lung Cancer. 2011 May;12(3):155-60. doi: 10.1016/j.cllc.2011.03.015. Epub 2011 Apr 27.

PMID:
21663857
18.

Second-line paclitaxel/carboplatin versus vinorelbine/carboplatin in patients who have advanced non-small-cell lung cancer pretreated with non-platinum-based chemotherapy: a multicenter randomized phase II study.

Pallis AG, Syrigos K, Kotsakis A, Karachaliou N, Polyzos A, Chandrinos V, Varthalitis I, Christophyllakis C, Ardavanis A, Vamvakas L, Vardakis N, Saridaki Z, Samonis G, Giassas S, Georgoulias V, Agelaki S.

Clin Lung Cancer. 2011 Mar;12(2):100-5. doi: 10.1016/j.cllc.2011.03.004. Epub 2011 Apr 11.

PMID:
21550556
19.

Efficacy and treatment tolerance in older patients with NSCLC: a meta-analysis of five phase III randomized trials conducted by the Hellenic Oncology Research Group.

Pallis AG, Karampeazis A, Vamvakas L, Vardakis N, Kotsakis A, Bozionelou V, Kalykaki A, Hatzidaki D, Mavroudis D, Georgoulias V.

Ann Oncol. 2011 Nov;22(11):2448-55. doi: 10.1093/annonc/mdq772. Epub 2011 Mar 10.

PMID:
21393380
20.

Prognostic significance of the detection of peripheral blood CEACAM5mRNA-positive cells by real-time polymerase chain reaction in operable colorectal cancer.

Vardakis N, Messaritakis I, Papadaki C, Agoglossakis G, Sfakianaki M, Saridaki Z, Apostolaki S, Koutroubakis I, Perraki M, Hatzidaki D, Mavroudis D, Georgoulias V, Souglakos J.

Clin Cancer Res. 2011 Jan 1;17(1):165-73. doi: 10.1158/1078-0432.CCR-10-0565. Epub 2010 Nov 11.

Supplemental Content

Loading ...
Support Center